Skip to content

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04250779
Acronym
MOMMIASTHMA1
Enrollment
50
Registered
2020-01-31
Start date
2019-07-01
Completion date
2021-12-01
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Medication, Asthma, Childhood Asthma

Brief summary

Asthma affects over 10 million children in the U.S., and poses a significant health and cost burden. Metered dose inhaler (MDI) is the most common method of treatment. Studies show that up to 80% of patients demonstrate incorrect use of MDIs, which results in suboptimal medication delivery to the lungs. Asthma control can be followed by symptoms, rescue medication usage and measures of airflow obstruction. Current options to monitor control include an asthma diary (relies on consistent use by the patient), pharmacy records of medication dispensing (dispensing does not equal usage), and peak expiratory flow (PEF) meters (significant variability in technique leading to inconsistent results). CapMedic is a smart inhaler and home spirometer device which aims to assist with correct MDI usage and to monitor asthma control. CapMedic fits on top of the MDI inhaler and provides live audio-visual-haptic cues to guide the patient for correctly using their inhaler. CapMedic includes a built-in forced expiratory flow in 1 second (FEV1, a measure of airflow) and PEF meter. It will utilize the same audio-visual-haptic hardware to implement live cues that encourage patient's effort in performing accurate at-home FEV1/PEF test. Cap will also be able to log medication usage and Medic application will allow patients to keep an asthma symptom diary.

Detailed description

CapMedic is a smart inhaler and home spirometer device which aims to assist with correct MDI usage and to monitor asthma control. CapMedic fits on top of the MDI inhaler and provides live audio-visual-haptic cues to guide the patient for correctly using their inhaler. CapMedic includes a built-in forced expiratory flow in 1 second (FEV1, a measure of airflow) and PEF meter. It will utilize the same audio-visual-haptic hardware to implement live cues that encourage patient's effort in performing accurate at-home FEV1/PEF test. Cap will also be able to log medication usage and Medic application will allow patients to keep an asthma symptom diary.

Interventions

DEVICECapMedic smart inhaler device

The CapMedic device provides active coaching to promote correct and regular use of MDI.

BEHAVIORALVideo-based guidance

Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.

Sponsors

Cognita Labs LLC
CollaboratorINDUSTRY
Landon Pediatric Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Intervention model description

Research will initially involve collection of data describing the participants' current use of their medication following standard education. Subsequent phases will add audio / haptic coaching to the process of administering medication by MDI, and follow the same participants to determine whether or not there is improvement in technique and adherence to therapy. The device will be used with a placebo inhaler (given AFTER the participant's regular medication is taken by standard techniques), to determine how participants use the device, and to identify the most effective coaching interventions for this age group. This is to ensure that the device does not interfere with delivery of routine asthma controller medications. The data will be used to develop a subsequent, longer term study in which we will evaluate the effect of the coaching device on asthma control, when it is used with the subject's controller medication.

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Asthma * Regular user of MDI * Asthma Control Test (ACT) scores between 15 and 25 * FEV1 between 60-80% of predicted (persistent mild-moderate) * Disease severity in the range mild-moderate * Access to a Smartphone and internet during the entire duration of the study. * Cognitively able to utilize the device and express interest in participating.

Exclusion criteria

* Patients without asthma * With developmental disabilities * Do not speak English * Do not own a Smartphone

Design outcomes

Primary

MeasureTime frameDescription
MDI use Competence in Clinic1 dayCorrectness of Inhaler Use measured using CapMedic device during recruitment. Competence is measured as a score out of 4 for 4 steps of MDI use: 1. Shaking, 2. Orientation, 3. Coordination 4. Duration of inhalation
MDI use Competence at home8 weeksCorrectness of Inhaler Use measured using CapMedic device at home. Competence is measured as a score out of 4 for 4 steps of MDI use: 1. Shaking, 2. Orientation, 3. Coordination 4. Duration of inhalation

Secondary

MeasureTime frameDescription
PEF Lung Function at home8 weeksPEF measured using CapMedic device at home. PEF is measured in L/min.
PEF Lung Function in Clinic1 dayPEF measured using CapMedic device during recruitment. PEF is measured in L/min.
MDI use Adherence8 weeksRegularity of MDI use measured by CapMedic device at home, measured as a % of puffs taken per week compared to prescribed dosage.
FEV1 Lung Function at home8 weeksFEV1 measured using CapMedic device at home. FEV1 is measured in L.
FEV1 Lung Function in Clinic1 dayFEV1 measured using CapMedic device during recruitment. FEV1 is measured in L.

Countries

United States

Contacts

Primary ContactChris Landon, M.D.
chris.landon@ventura.org8053401366
Backup ContactEmilie Paronyan
emilieparonyann@gmail.com8184393664

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026